Aytu BioPharma, Inc. (AYTU) vs Marker Therapeutics, Inc. (MRKR)
A side-by-side comparison of Aytu BioPharma, Inc. and Marker Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AYTU
Aytu BioPharma, Inc.
$2.06HealthcareDelayed quote: Oct 6, 2026, 12:48 PM EDT
MRKR
Marker Therapeutics, Inc.
$1.02HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — AYTU vs MRKR
growth of $100 · dividends reinvested · last 10yAYTU -100.0% (-68.9%/yr)MRKR -98.3% (-33.4%/yr)MRKR compounded faster over this window
Log scale — wide-divergence pair
AYTU MRKR
AYTU vs MRKR: by the numbers
- •AYTU is the larger company ($22M vs $17M market cap).
- •Both run net losses; AYTU's is the smaller (-24.76% vs -706.23% net margin).
Metrics side by side
Valuation
| Metric | AYTU | MRKR |
|---|---|---|
| P/S ratio | 0.38 | 13.79 |
| P/B ratio | 0.63 | 1.40 |
| FCF yield | 14.71% | N/A |
Profitability
| Metric | AYTU | MRKR |
|---|---|---|
| Gross margin | 63.95% | 0.00% |
| Operating margin | -14.44% | 0.00% |
| Net margin | -24.76% | -706.23% |
| ROE | -40.40% | -71.57% |
| ROIC | -14.21% | -88.07% |
Growth (annualized)
| Metric | AYTU | MRKR |
|---|---|---|
| Revenue CAGR (5Y) | -2.59% | N/A |
| Total return CAGR (5Y) | -48.14% | -42.13% |
Frequently asked
- How have AYTU and MRKR total returns compared?
- Over the past 10 years, AYTU delivered -68.87% and MRKR delivered -33.25% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Aytu BioPharma ROEMarker Therapeutics ROEAytu BioPharma operating marginMarker Therapeutics operating marginAytu BioPharma revenue growthMarker Therapeutics revenue growthAytu BioPharma free cash flowMarker Therapeutics free cash flow
Aytu BioPharma & Marker Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.